148 related articles for article (PubMed ID: 34090645)
1. Imaging and its Impact on Defining the Oligometastatic State.
Pirasteh A; Lovrec P; Pedrosa I
Semin Radiat Oncol; 2021 Jul; 31(3):186-199. PubMed ID: 34090645
[TBL] [Abstract][Full Text] [Related]
2. Defining oligometastatic disease from a radiation oncology perspective: An ESTRO-ASTRO consensus document.
Lievens Y; Guckenberger M; Gomez D; Hoyer M; Iyengar P; Kindts I; Méndez Romero A; Nevens D; Palma D; Park C; Ricardi U; Scorsetti M; Yu J; Woodward WA
Radiother Oncol; 2020 Jul; 148():157-166. PubMed ID: 32388150
[TBL] [Abstract][Full Text] [Related]
3. Strategies and technical challenges for imaging oligometastatic disease: Recommendations from the European Organisation for Research and Treatment of Cancer imaging group.
deSouza NM; Liu Y; Chiti A; Oprea-Lager D; Gebhart G; Van Beers BE; Herrmann K; Lecouvet FE
Eur J Cancer; 2018 Mar; 91():153-163. PubMed ID: 29331524
[TBL] [Abstract][Full Text] [Related]
4. European clinical practice guidelines for the definition, diagnosis, and treatment of oligometastatic esophagogastric cancer (OMEC-4).
Kroese TE; Bronzwaer S; van Rossum PSN; Schoppman SF; Deseyne PRAJ; van Cutsem E; Haustermans K; Nafteux P; Thomas M; Obermannova R; Mortensen HR; Nordsmark M; Pfeiffer P; Elme A; Adenis A; Piessen G; Bruns CJ; Lordick F; Gockel I; Moehler M; Gani C; Liakakos T; Reynolds JV; Morganti AG; Rosati R; Castoro C; Cellini F; D'Ugo D; Roviello F; Bencivenga M; de Manzoni G; van Berge Henegouwen MI; Hulshoff MCCM; van Dieren J; Vollebergh M; van Sandick JW; Jeene P; Muijs C; Slingerland M; Voncken FEM; Hartgrink H; Creemers GJ; van der Sangen MJC; Nieuwenhuijzen GAP; Berbee M; Verheij M; Wijnhoven B; Beerepoot LV; Mohammad NH; Mook S; Ruurda JP; Kolodziejczyk P; Polkowski WP; Wyrwicz L; Alsina M; Tabernero J; Pera M; Kanonnikoff TF; Cervantes A; Nilsson M; Monig S; Wagner AD; Guckenberger M; Griffiths EA; Smyth E; Hanna GB; Markar S; Chaudry MA; Hawkins MA; Cheong E; van Laarhoven HWM; van Hillegersberg R;
Eur J Cancer; 2024 Jun; 204():114062. PubMed ID: 38678762
[TBL] [Abstract][Full Text] [Related]
5. Defining oligometastatic pancreatic cancer: a systematic review and critical synthesis of consensus.
Leonhardt CS; Stamm T; Hank T; Prager G; Strobel O
ESMO Open; 2023 Dec; 8(6):102067. PubMed ID: 37988953
[TBL] [Abstract][Full Text] [Related]
6. Imaging of Oligometastatic Disease.
Vietti Violi N; Hajri R; Haefliger L; Nicod-Lalonde M; Villard N; Dromain C
Cancers (Basel); 2022 Mar; 14(6):. PubMed ID: 35326586
[TBL] [Abstract][Full Text] [Related]
7. A risk-based approach to identifying oligometastatic disease on imaging.
deSouza NM; Tempany CM
Int J Cancer; 2019 Feb; 144(3):422-430. PubMed ID: 30098215
[TBL] [Abstract][Full Text] [Related]
8. Unravelling oligometastatic disease from the perspective of radiation and medical oncology. Part II: prostate cancer and colorectal cancer.
Conde-Moreno AJ; González-Del-Alba A; López-Campos F; López López C; Requejo OH; de Castro Carpeño J; Chicas-Sett R; de Paz Arias L; Montero-Luis Á; Pérez AR; Font EF; Arija JÁA
Clin Transl Oncol; 2023 Apr; 25(4):897-911. PubMed ID: 36525230
[TBL] [Abstract][Full Text] [Related]
9. A review of ongoing trials of stereotactic ablative radiotherapy for oligometastatic disease in the context of new consensus definitions.
Li GJ; Arifin AJ; Al-Shafa F; Cheung P; Rodrigues GB; Palma DA; Louie AV
Ann Palliat Med; 2021 May; 10(5):6045-6051. PubMed ID: 32787370
[TBL] [Abstract][Full Text] [Related]
10. Metastasis-directed Therapy in Prostate Cancer: Prognostic Significance of the ESTRO/EORTC Classification in Oligometastatic Bone Disease.
Nicholls L; Chapman E; Khoo V; Suh YE; Tunariu N; Wang Y; van As N
Clin Oncol (R Coll Radiol); 2022 Jan; 34(1):63-69. PubMed ID: 34756755
[TBL] [Abstract][Full Text] [Related]
11. Oligometastatic Disease Detection with
Artigas C; Diamand R; Shagera QA; Plouznikoff N; Fokoue F; Otte FX; Gil T; Peltier A; Van Gestel D; Flamen P
Cancers (Basel); 2021 Oct; 13(19):. PubMed ID: 34638466
[TBL] [Abstract][Full Text] [Related]
12. Approach to Oligometastatic Cancer in the Elderly Patient.
Winter IW; Smile TD; Videtic GMM
Curr Oncol Rep; 2021 Aug; 23(11):122. PubMed ID: 34448967
[TBL] [Abstract][Full Text] [Related]
13. Multimodal imaging of occult macular dystrophy.
Ahn SJ; Ahn J; Park KH; Woo SJ
JAMA Ophthalmol; 2013 Jul; 131(7):880-90. PubMed ID: 24010148
[TBL] [Abstract][Full Text] [Related]
14. Local ablative treatment for synchronous single organ oligometastatic lung cancer-A propensity score analysis of 180 patients.
Frost N; Tessmer A; Schmittel A; van Laak V; Raspe M; Ruwwe-Glösenkamp C; Brunn M; Senger C; Böhmer D; Ochsenreither S; Temmesfeld-Wollbrück B; Furth C; Schmidt B; Neudecker J; Rückert JC; Suttorp N; Witzenrath M; Grohé C
Lung Cancer; 2018 Nov; 125():164-173. PubMed ID: 30429016
[TBL] [Abstract][Full Text] [Related]
15. Oligo-metastatic neoPlasms from the gastro-intestinal tract: iDentIfiCaTIon of cliNical and molecular drivers: the PREDICTION study.
Ottaiano A; De Luca A; Santorsola M; Scognamiglio G; Di Mauro A; Chiodini P; Lambiase M; Sacco A; Petrillo A; Granata V; Fusco R; Mercadante E; Martucci N; De Luca G; Rocca A; Celentano E; Crispo A; Di Gennaro P; Tatangelo F; Ferrara G; Izzo F; Belli A; Patrone R; Delrio P; Rega D; De Franciscis S; Muto P; Ravo V; Di Franco R; Borzillo V; Santagata S; Rea G; Castaldo D; Pace U; De Feo G; Scala S; Nasti G; Normanno N
BMC Cancer; 2023 Oct; 23(1):1010. PubMed ID: 37858132
[TBL] [Abstract][Full Text] [Related]
16. Highlights on the Management of Oligometastatic Disease.
Alshehri SM; Alkattan K; Abdelwarith A; Alhussain H; Shaker S; Alghamdi M; Alassaf H; Albargawi A; Naimi MA; Alomair A; Althaqfi S; Alhebshi A; Alothman M; Jazieh A
J Immunother Precis Oncol; 2020 Feb; 3(1):34-44. PubMed ID: 35756179
[No Abstract] [Full Text] [Related]
17. Is Oligometastatic Cancer Curable? A Survey of Oncologist Perspectives, Decision Making, and Communication.
Cho HL; Balboni T; Christ SM; Turner B; Spektor A; Perni S
Adv Radiat Oncol; 2023; 8(5):101221. PubMed ID: 37124028
[TBL] [Abstract][Full Text] [Related]
18. Oligometastatic colorectal cancer: prognosis, role of locoregional treatments and impact of first-line chemotherapy-a pooled analysis of TRIBE and TRIBE2 studies by Gruppo Oncologico del Nord Ovest.
Moretto R; Rossini D; Zucchelli G; Lonardi S; Bergamo F; Santini D; Cupini S; Tomasello G; Caponnetto S; Zaniboni A; Antoniotti C; Pietrantonio F; Buonadonna A; Marmorino F; Bordonaro R; Fea E; Tamburini E; Boccaccino A; Grande R; Aprile G; Falcone A; Cremolini C
Eur J Cancer; 2020 Nov; 139():81-89. PubMed ID: 32979645
[TBL] [Abstract][Full Text] [Related]
19. Positron Emission Tomography and Whole-body Magnetic Resonance Imaging for Metastasis-directed Therapy in Hormone-sensitive Oligometastatic Prostate Cancer After Primary Radical Treatment: A Systematic Review.
Farolfi A; Hadaschik B; Hamdy FC; Herrmann K; Hofman MS; Murphy DG; Ost P; Padhani AR; Fanti S
Eur Urol Oncol; 2021 Oct; 4(5):714-730. PubMed ID: 33750684
[TBL] [Abstract][Full Text] [Related]
20. Evolution of treatment strategies for oligometastatic NSCLC patients - A systematic review of the literature.
Schanne DH; Heitmann J; Guckenberger M; Andratschke NHJ
Cancer Treat Rev; 2019 Nov; 80():101892. PubMed ID: 31522079
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
